AI-Powered Multiplatform Ecosystem for Drug Discovery

Our indication- and target-agnostic platforms accelerate small molecule and peptide design, delivering precision workflows for complex drug discovery through an integrated, AI-driven ecosystem.

Monospecific

Small molecules

Linear peptides

Cyclic peptides

Peptidomimetics

Bispecific

Internalisation and relocalization enhancers

Protein proximity engagers

Degraders (PROTACs/LYTACs)

Membranotropic conjugates

PPI modulators

Predicting PPI interfaces

PPI disruptors

PPI stabilisers

Molecular glues

Antibody mimetics

Addressing targets validated by antibodies

High permeability

High selectivity

Oral administration

Induced Proximity Platform

Ternary complex prediction

Protein degraders

Molecular glues

PPI disruptors

Monospecific Compounds Platform

Covalent/non-covalent drugs

Cyclic/hybrid peptides drugs

GPCRs, Kinases, Ion channels

Enzymes, Nuclear receptors

Drug Conjugates Platform

Payload-linker systems

Targeting ligands

DNA/RNA-conjugates

Radiolabeled, ADCs, PDCs

End-to-end Drug Discovery for Precision Medicine

Our platform is tailored to the patient specific targets and allows designing highly selective and potent drug candidates with a high success rate

Target
Identification

Advanced identification of potential targets for precision medicine using best-in-class omics and population-level data analysis

Drug Candidate Design

40+ proprietary AI models are applied to design novel drugs for precision medicine using proprietary multi-level selectivity assessment

Experimental Feedback via Active Learning

Iterative experimental feedback integration from In vitro, in vivo and structure determination techniques to enforce target specificity.

End-to-end Drug Discovery
for Precision Medicine